April 17, 2024

2 Minutes
Medicine

Novartis Fabhalta Data Show Statistically Significant Proteinuria Reduction of 38.3% Versus Placebo

On April 15th, Novartis presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy...
Read More